OTCMKTS:ASPHF Ascentage Pharma Group International (ASPHF) Stock Price, News & Analysis $5.83 0.00 (0.00%) As of 07/3/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Ascentage Pharma Group International Stock (OTCMKTS:ASPHF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ASPHF alerts:Sign Up Key Stats Today's Range$5.83▼$5.8350-Day Range$5.83▼$5.8352-Week Range$5.42▼$6.45VolumeN/AAverage Volume500 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation. It also has APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449, an oral bioavailable inhibitor of FAK, ROS1, and ALK tyrosine kinases; APG-5918, an orally available and selective EED inhibitor; APG-265, a MDM2 protein degrade; and UBX1967/1325. In, addition it engages in medical research and development; venture capital investment; and rental services. The company has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China. Read More Receive ASPHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Email Address ASPHF Stock News HeadlinesAscentage Pharma Grants Further RSUs to Employees Under 2021 SchemeJune 27, 2025 | tipranks.comAscentage Pharma Reports Promising Study Results at EHA 2025June 15, 2025 | tipranks.com140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, Apple, and Amazon. And for the July 4th holiday...I'm sharing this secret for just $9. | Investors Alley (Ad)Ascentage Pharma Group International (AAPG) Showcases Innovative Cancer Treatments at 2025 EHA ...June 9, 2025 | gurufocus.comAscentage Pharma Unveils Promising Clinical Data at ASCO 2025May 22, 2025 | tipranks.comAscentage Pharma Unveils Promising Preclinical Results at AACR 2025April 28, 2025 | tipranks.comAscentage Pharma Advances 2022 RSU Scheme with Share PurchaseApril 8, 2025 | tipranks.comAscentage Pharma Advances 2022 RSU Scheme with Share PurchaseMarch 31, 2025 | tipranks.comSee More Headlines ASPHF Stock Analysis - Frequently Asked Questions How have ASPHF shares performed this year? Ascentage Pharma Group International's stock was trading at $6.45 at the beginning of 2025. Since then, ASPHF shares have decreased by 9.7% and is now trading at $5.8250. How do I buy shares of Ascentage Pharma Group International? Shares of ASPHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:ASPHF CIKN/A Webwww.ascentagepharma.com Phone86-512-8555-7777FaxN/AEmployees565Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:ASPHF) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.